JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.86 CNY | -3.65% |
|
-3.79% | -23.01% |
| Sales 2022 | 830M 115M 157M | Sales 2023 | 854M 118M 161M | Capitalization | 2.95B 407M 556M |
|---|---|---|---|---|---|
| Net income 2022 | 83M 11.45M 15.66M | Net income 2023 | 94M 12.97M 17.74M | EV / Sales 2022 | 3.28 x |
| Net Debt 2022 | 40.44M 5.58M 7.63M | Net cash position 2023 | 114M 15.72M 21.49M | EV / Sales 2023 | 3.32 x |
| P/E ratio 2022 |
32.3
x | P/E ratio 2023 |
31.1
x | Employees | 1,678 |
| Yield 2022 |
0.62% | Yield 2023 |
1.68% | Free-Float | 52.64% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.65% | ||
| 1 week | -3.79% | ||
| Current month | -4.85% | ||
| 1 month | -2.14% | ||
| 3 months | -14.78% | ||
| 6 months | -18.24% | ||
| Current year | -23.01% |
1 week
6.63
7.29
1 month
6.087.42
Current year
5.209.58
1 year
5.2010.21
3 years
5.2012.34
5 years
5.2012.34
10 years
5.2026.87
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Min Xie
CEO | Chief Executive Officer | 66 | 08-12-31 |
Jian Tao Bi
DFI | Director of Finance/CFO | 54 | 11-07-31 |
Tie Jun Li
PSD | President | 64 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Rong Sun
BRD | Director/Board Member | 68 | 22-05-10 |
Ming Li
BRD | Director/Board Member | 62 | 19-05-07 |
Yi Sheng Zhang
CHM | Chairman | 68 | 99-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.86 | -3.65% | 12,354,530 |
| 24-04-25 | 7.12 | +2.45% | 7,281,600 |
| 24-04-24 | 6.95 | +1.02% | 6,787,400 |
| 24-04-23 | 6.88 | +2.08% | 10,164,100 |
| 24-04-22 | 6.74 | -5.47% | 19,097,800 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and distribution of Chinese patent drugs for the treatment of cardiovascular and cerebrovascular disease. The Companyâs main products consist of Shengmai injections, Zhenyuan capsules, Xinyue capsules, Qingkailing injections and Guifu Dihuang capsules, among others. The Company's products are applied in the treatment for heart cerebrovascular diseases and detoxification. The company also provides health care products and cosmetics. The Company distributes its products within China market.
Sector
Pharmaceuticals
Calendar
2024-05-10
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -23.01% | 313M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002566 Stock
